31 results about "Squamous cell carcinoma Antigen" patented technology

In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.

The invention discloses a method for enhancing the luminous intensity of a squamous-cell carcinoma antigen during electrochemical luminescence detection. The method mainly comprises a construction step of an electrochemical luminescence sensor, wherein the construction step comprises: preparing an SCCA solution with certain concentration, dripping the SCCA on a polymer molecular imprinting modified electrode for incubation, performing washing with water after the incubation is completed, then dripping a Fe-MIL-88-NH2 @ZnSe/Ab/BSA complex onto the electrode and incubating the same, performing washing with water after the incubation is completed, and drying to obtain the electrochemical luminescence sensor; and the prepared electrochemical luminescence sensor is placed in a PBS buffer solution containing a co-reactant to perform electrochemical luminescence detection, and then the luminous intensity of the SCCA during the electrochemical luminescence detection can be effectively. The electrochemical luminescence sensor constructed by the method disclosed by the invention has good selectivity and high sensitivity, and when the electrochemical luminescence sensor is applied to the electrochemical luminescence detection of the SCCA, the linear range of the method is effectively increased, and the detection sensitivity is improved.

The present invention relates to novel antibodies, antibody fragments and antibody conjugates which display a high degree of selectivity for squamous cell carcinoma antigens including carcinomas of the lung, esophagus and cervix. The present invention relates to both in vivo and in vitro clinical screening methods for diagnosis or prognosis of carcinomas by means of detecting the expression of squamous cell carcinoma antigens in biological samples of the subject using the novel antibodies of the invention. The invention further provides for kits for carrying out the above described screening methods. Additionally, antibody conjugates may be used to efficiently deliver various agents which have anti-tumor effects to the tumor cell. The antibodies of the invention may also be administered to a patient in non-conjugated form to target ADCC to the tumor cell.

The invention relates to a biomarker-spectrum-based lung cancer risk prediction kit for high-risk groups in rural China.The kit comprises reagents for measuring the serum protein spectrum expression quantity of the four biomarkers comprising gastrin release propeptide, the carcino-embryonic antigen, the cytokeratin 19 fragment and the squamous-cell carcinoma antigen.The kit is combined with other clinical indexes such as the age, smoking history, malignancy history and sex, and can be used for accurately predicting the lung cancer risk.

The invention provides a chemiluminescent immunoassay quantitative detection kit for squamous cell carcinoma antigens, which relates to the medical field of immunoassay. The kit of the invention is mainly composed of a squamous cell carcinoma antigenic temporary calibrator, a solid-phase vector which is coated by a squamous cell carcinoma antigenic antibody, a squamous cell carcinoma antigenic antibody which is marked by enzyme, a chemiluminescent substrate solution and a concentrated washing solution. The preparation method of the kit mainly comprises the following steps: the coating of the solid-phase vector, the preparation of the calibrator and enzyme markers and the preparation of the chemiluminescent substrate solution and the concentrated washing solution. With the kit and the preparation method thereof, the detection sensitivity, the linear range and the quantitative accuracy can be improved. The invention has convenient use, safety and stability.